智通财经APP讯，加科思-B(01167)公布，公司自主研发的Pan-KRAS抑制剂AB-23E73的新药临床试验申请(IND)已经获得国家药品监督管理局(NMPA) 药品审评中心(CDE)批准。此前，美国的IND申请也已经获得美国食品药品监督管理局(FDA)批准，将在中国和美国同步开展I/IIa期晚期实体瘤临床试验。
KRAS广泛存在于多种肿瘤突变，约23%-25%的癌症患者带有KRAS突变，全球每年新增约270万带有KRAS相关突变的肿瘤患者有望从Pan-KRAS抑制剂中获益。
JAB-23E73可同时抑制KRAS的活性及非活性状态的KRAS，并对HRAS、NRAS 无明显抑制。作为口服KRAS抑制剂，JAB-23E73的临床前资料展现了良好的药代动力学特性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.